AB Science (AB.PA) Stock Price
AB Science Price
Revenue has compounded at 8.5% per year over the past 16 years to 1.17 M EUR. AB Science's net margin stands at -132.6%, up from -900.0% several years earlier. The stock trades about 40% above its 52-week low.
AB Science stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of AB Science over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AB Science stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AB Science's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | AB Science Price |
|---|---|
| 9/21/2026 | 0.71 EUR |
| 9/18/2026 | 0.72 EUR |
| 9/17/2026 | 0.71 EUR |
| 9/16/2026 | 0.72 EUR |
| 9/15/2026 | 0.71 EUR |
| 9/14/2026 | 0.72 EUR |
| 9/11/2026 | 0.73 EUR |
| 9/10/2026 | 0.71 EUR |
| 9/9/2026 | 0.72 EUR |
| 9/8/2026 | 0.73 EUR |
| 9/7/2026 | 0.73 EUR |
| 9/4/2026 | 0.73 EUR |
| 9/3/2026 | 0.73 EUR |
| 9/2/2026 | 0.76 EUR |
| 9/1/2026 | 0.74 EUR |
| 8/31/2026 | 0.70 EUR |
| 8/28/2026 | 0.73 EUR |
| 8/27/2026 | 0.74 EUR |
| 8/26/2026 | 0.71 EUR |
| 8/25/2026 | 0.74 EUR |
| 8/21/2026 | 0.69 EUR |
| 8/20/2026 | 0.69 EUR |
| 8/19/2026 | 0.69 EUR |
| 8/18/2026 | 0.71 EUR |
| 8/17/2026 | 0.72 EUR |
| 8/14/2026 | 0.74 EUR |
| 8/13/2026 | 0.72 EUR |
| 8/12/2026 | 0.75 EUR |
| 8/11/2026 | 0.77 EUR |
| 8/10/2026 | 0.75 EUR |
AB Science Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
AB Science Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEk EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | – | – | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| – | 100.00 | – | -50.00 | – | – | – | – | – | – | – | – | – | – | – | – |
| 100.00 | 50.00 | 50.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | – | – | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 |
| -13.00 | -15.00 | -25.00 | -30.00 | -28.00 | -28.00 | -17.00 | -14.00 | -13.00 | -15.00 | -13.00 | -6.00 | -8.00 | -6.00 | -6.00 | -1.00 |
| -1,300.00 | -750.00 | -1,250.00 | -3,000.00 | -2,800.00 | -2,800.00 | -1,700.00 | -1,400.00 | -1,300.00 | – | – | -600.00 | -800.00 | -600.00 | -600.00 | -100.00 |
| -14.00 | -16.00 | -26.00 | -27.00 | -27.00 | -26.00 | -21.00 | -15.00 | -14.00 | -13.00 | -11.00 | -7.00 | -10.00 | -9.00 | -9.00 | – |
| 40.00 | 14.29 | 62.50 | 3.85 | – | -3.70 | -19.23 | -28.57 | -6.67 | -7.14 | -15.38 | -36.36 | 42.86 | -10.00 | – | – |
| 32.83 | 32.94 | 34.20 | 35.65 | 35.99 | 37.78 | 39.40 | 44.23 | 47.52 | 47.14 | 49.66 | 53.27 | 53.27 | 53.27 | 53.27 | 53.27 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales AB Science generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AB Science retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AB Science's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares AB Science has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AB Science's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
AB Science stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
AB Science Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
AB Science business model & stock analysis
AB Science SWOT Analysis
Strengths
AB Science SA possesses several strengths that contribute to its success:
- Strong research and development capabilities
- Robust and innovative product portfolio
- Proven track record in conducting clinical trials
- Positive brand reputation in the pharmaceutical industry
- Strong financial position and ability to invest in new opportunities
Weaknesses
Despite its strengths, AB Science SA also faces certain weaknesses:
- Dependency on a limited number of key products
- Reliance on external partnerships for drug development and distribution
- Lack of geographical diversification in its operations
- Vulnerability to changes in regulatory frameworks and policies
- Limited market share compared to larger pharmaceutical companies
Opportunities
AB Science SA can leverage the following opportunities to further its growth:
- Expanding into new markets and geographical regions
- Licensing or acquiring complementary technologies or products
- Leveraging advancements in precision medicine and personalized therapies
- Collaborating with academic and research institutions to accelerate innovation
- Taking advantage of government initiatives and funding for research and development
Threats
AB Science SA needs to be cautious of the following potential threats:
- Intense competition from larger pharmaceutical companies
- Stringent regulatory requirements and approval processes
- Economic downturns impacting healthcare budgets and spending
- Emergence of generic alternatives to AB Science SA's products
- Technological advancements rendering existing therapies obsolete
AB Science Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
AB Science historical P/E ratio, EBIT multiple, and P/S ratio
AB Science annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down AB Science's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in AB Science's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare AB Science's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
AB Science shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
AB Science Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 9/25/2026 | -0.07EUR | - | 600,000.00EUR | - | 2026 Q3 |
| 5/13/2026 | -0.07EUR | -0.07EUR | 500,000.00EUR | - | 2026 Q1 |
| 9/30/2025 | -EUR | -0.09EUR | 497,247.00EUR | - | 2025 Q3 |
| 4/28/2023 | -0.76EUR | -0.14EUR | 1.60 MEUR | - | 2023 Q1 |
| 9/30/2022 | -0.76EUR | -0.15EUR | 2.03 MEUR | - | 2022 Q3 |
| 4/29/2022 | -0.57EUR | -0.21EUR | 2.03 MEUR | - | 2022 Q1 |
| 9/30/2021 | -0.57EUR | -0.10EUR | 2.03 MEUR | - | 2021 Q3 |
| 4/30/2021 | -0.17EUR | -0.14EUR | 900,000.00EUR | - | 2021 Q1 |
| 10/1/2020 | -0.16EUR | -0.23EUR | 900,000.00EUR | - | 2020 Q3 |
| 4/30/2020 | -0.26EUR | -0.21EUR | 800,000.00EUR | - | 2020 Q1 |
EESG©
Eulerpool ESG Scorecard© for the AB Science stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
AB Science Executives and Management Board
8 members · avg. age 63 · 38 % women
Mr. Alain Moussy
Chairman of the Board, Chief Executive Officer · since 2001
495,000.00 EUR
Management
Mr. Denis Gicquel
Deputy Chief Executive Officer
Mr. Laurent Guy
Chief Financial Officer
Board of Directors
Mr. Patrick Moussy
Director
Ms. Cecile de Guillebon (63)
Independent Director
Ms. Catherine Johnston-Roussillo
Independent Director
Ms. Guillemette Latscha
Independent Director
Mr. Renaud Sassi
Independent Director
AB Science Supply Chain
Frequently asked questions about AB Science
AB Science SA is a biopharmaceutical company that focuses on research, development, and commercialization of targeted therapies. Their business model centers around the discovery and development of innovative drugs for various medical conditions, including oncology, neurology, and rare diseases. AB Science SA aims to improve patient outcomes and quality of life by utilizing their proprietary technology and conducting rigorous clinical trials. By combining scientific expertise with a patient-centric approach, AB Science SA strives to bring novel treatments to market, addressing unmet medical needs. With a commitment to innovation and research, AB Science SA continues to pave the way in the field of personalized medicine.
AB Science SA is primarily active in the pharmaceutical industry.
The main competitors of AB Science SA in the market are other pharmaceutical companies operating in the same therapeutic areas. These include major players such as Novartis, Pfizer, and Roche. AB Science SA faces competition in the development and commercialization of its products, particularly in the fields of oncology and rare diseases. The company strives to differentiate itself through its innovative pipeline and unique research approach. However, it operates in a highly competitive landscape where technological advancements and regulatory challenges play a significant role in shaping market dynamics.
AB Science SA is a renowned biopharmaceutical company founded in 2001. Headquartered in France, AB Science is dedicated to developing innovative therapies for life-threatening diseases with unmet medical needs. The company focuses on developing small molecules targeting tyrosine kinase receptors. AB Science has a robust pipeline with a particular focus on oncology, inflammatory diseases, and neurodegenerative disorders. With a strong commitment to research and development, AB Science strives to improve patient outcomes through its cutting-edge therapeutic solutions. As a leading player in the biopharmaceutical industry, AB Science SA continues to make significant contributions to the advancement of medical science.
AB Science SA has achieved significant milestones in its journey. The company has successfully conducted extensive clinical trials, gaining regulatory approvals for its innovative therapies. AB Science SA has also secured strategic partnerships and collaborations with renowned institutes and organizations, enhancing its research and development capabilities. The company's commitment to scientific excellence has led to breakthrough discoveries and advancements in the field. With its continuous efforts and dedication, AB Science SA has emerged as a leader in the industry, delivering novel solutions and improving patient outcomes.
AB Science SA is primarily present in various countries and regions around the world. Some of the key areas where AB Science SA operates include France, the United States, and several European countries. With its headquarters located in Paris, France, AB Science SA has established a significant presence in the pharmaceutical industry globally. The company's dedication to innovative research and development in the field of targeted therapies has contributed to its global footprint, expanding its reach and influence in multiple markets to address various unmet medical needs.
AB Science SA represents values of innovation, commitment, and scientific rigor. As a biopharmaceutical company, AB Science SA focuses on developing cutting-edge therapies to address unmet medical needs. With a strong corporate philosophy that values patient-centricity and scientific excellence, AB Science SA is dedicated to advancing the understanding and treatment of severe diseases. Their commitment to research and development, alongside a patient-focused approach, drives their mission to improve the lives of patients worldwide. Through their groundbreaking discoveries and relentless pursuit of scientific advancements, AB Science SA is at the forefront of delivering innovative therapeutic solutions.
9 analysts currently rate the AB Science stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AB Science to generate revenue of 1.20 M EUR and earnings per share of -0.14 EUR.
The AB Science share (AB.PA) is listed on 8 stock exchanges, including: London (0Q77.L), Frankfurt (A8D.F), München (A8D.MU), Düsseldorf (A8D.DU), Paris (AB.PA).
The French company AB Science SA is a biopharmaceutical company specializing in the development and marketing of innovative therapies for rare diseases and serious neurological conditions. The company's business model is based on creating and implementing a comprehensive and integrated portfolio of drug candidates for various diseases. AB Science combines internal research and development activities with strategic partnerships with leading academic institutions and companies in the healthcare field. AB Science's product range includes various drug candidates for rare and serious neurological diseases such as stomach cancer, amyotrophic lateral sclerosis (ALS), mastocytosis (a rare disease causing an excessive number of mast cells in the body), and Alzheimer's disease. One of the company's most promising products is Masitinib, an oral selective tyrosine kinase inhibitor currently undergoing phase 3 clinical trials for various indications. AB Science's business model consists of multiple divisions, each specializing in the development and marketing of drugs for specific diseases. The first division focuses on developing therapies for stomach cancer, with AB Science already having developed a highly effective treatment for this disease. The company plans to bring this medication to market soon. Another division of AB Science focuses on developing drugs for ALS, with the company currently testing a promising drug candidate called Masitinib in phase 3 clinical trials. The goal is to obtain approval for Masitinib as soon as possible and make it available to millions of ALS patients worldwide. Another important division of AB Science focuses on developing drugs for mastocytosis, with the company already having developed a highly effective treatment for this disease. The company plans to bring this medication to market soon. In addition to drug development, AB Science also collaborates closely with other companies and academic institutions to identify and develop new compounds and technologies. With its extensive experience in researching rare diseases and its innovative research and development of therapies, the company will remain a key player in the biopharmaceutical industry in the future. Overall, AB Science's business model is focused on creating and implementing a robust portfolio of drug candidates for rare and serious neurological diseases. The company relies on a combination of research and development, strategic partnerships, and experienced management to develop and market therapies for patients worldwide. With its diverse product portfolio and commitment to improving patients' quality of life, AB Science will continue to be a leading company in the biopharmaceutical industry.
The expected revenue of AB Science is 1.20 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of AB Science is -9.93 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of AB Science is currently -5.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AB Science stock.
The price-to-sales ratio (P/S) of AB Science is currently 43.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AB Science stock.
The Eulerpool Quality Score for AB Science is 2/10.
The ISIN of AB Science is FR0010557264. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of AB Science is A1CXBG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of AB Science is AB.PA. The ticker symbol is used to trade AB Science shares on the stock exchange.
AB Science paid dividends every year for the past 0 years.
AB Science is assigned to the 'Health' sector.
The dividends of AB Science are distributed in EUR.
AB Science stock
AB Science Peer Group
AB Science Ticker
AB Science FIGI
All fundamentals and in-depth analysis of AB Science
Our stock analysis for AB Science stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AB Science. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.